

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the **October 1, 2020** Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at www.ab.bluecross.ca/dbl/publications.php.

Please refer to the October 1, 2020, updates for complete listings of products available by restricted benefit/special authorization, products with changes to criteria for coverage, added products, least cost alternative (LCA) price changes, products with a price change, and discontinued listings.

Please note that the online Interactive Drug Benefit List (iDBL) at www.ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application, and as such, contains the most up-to-date information.

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Sandoz Canada Inc. that the shortage for Sandoz Valsartan 160 mg Tablet (DIN 02356767) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 22, 2020**. The following grouping was removed from the Critical Supply Product List **September 23, 2020**.

VALSARTAN

160 MG TABLET

00002414236	AURO-VALSARTAN	AUR	\$ 0.2159
00002363119	RAN-VALSARTAN	RAN	\$ 0.2159
00002356767	SANDOZ VALSARTAN	SDZ	\$ 0.2159
00002356678	TEVA-VALSARTAN	TEV	\$ 0.2159
00002244782	DIOVAN	NOV	\$ 1.2825

Removal of temporary benefits from the Alberta Drug Benefit List (ADBL)

Due to the shortages of the following products: Auro-Valsartan 40 mg Tablet (DIN 02414201) manufactured by Auro Pharma Inc., Ran-Valsartan 40 mg Tablet (DIN 02363062) manufactured by Ranbaxy Pharmaceuticals Canada Inc, Teva-Valsartan 40 mg Tablet (DIN 02356643) manufactured by Teva Canada Limited and Diovan 40 mg Tablet (DIN 02270528) manufactured by Novartis Pharmaceuticals Canada Inc. were added as temporary benefits for the *Alberta Drug Benefit List (ADBL)*.

DIN	Product Description	Manufacturer
02414228	Auro-Valsartan 80 mg Tablet	Auro Pharma Inc.
02403331	Ran-Valsartan 80 mg Tablet	Ranbaxy Pharmaceuticals Canada Inc
02445972	Sandoz Valsartan 80 mg Tablet	Sandoz Canada Inc.
02398842	Teva-Valsartan 80 mg Tablet	Teva Canada Limited
02244781	Diovan 80 mg Tablet	Novartis Pharmaceuticals Canada Inc.

Sandoz Canada Inc. and Novartis Pharmaceuticals Canada Inc. have advised Alberta Blue Cross that the shortages of Sandoz Valsartan 80 mg Tablet (DIN 02445972) and Diovan 80 mg Tablet (DIN 02244781) respectively, have been resolved. These products were removed from the Critical Supply Product List **September 9, 2020**.

As a result, Auro-Valsartan 40 mg Tablet (DIN 02414201), Ran-Valsartan 40 mg Tablet (DIN 02363062), Teva-Valsartan 40 mg Tablet (DIN 02356643) and Diovan 40 mg Tablet (DIN 02270528) will no longer be considered temporary benefits for the ADBL after **October 9, 2020**.

continued on next page ...

... continued from previous page

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Apotex Inc., Sivem Pharmaceuticals ULC, Sanis Health Inc., Accord Healthcare Inc., Jamp Pharma Corporation, Mint Pharmaceuticals Inc., Pharmascience Inc., and Teva Canada Limited that the shortages for Apo-Candesartan 16 mg Tablet (DIN 02365367), Candesartan 16 mg Tablet (DIN 02388715), Candesartan 16 mg Tablet (DIN 02388936), Candesartan Cilexetil 16 mg Tablet (DIN 02379287), Jamp-Candesartan 16 mg Tablet (DIN 02386526), Mint-Candesartan 16 mg Tablet (DIN 02476924), pms-Candesartan 16 mg Tablet (DIN 02391201) and Teva-Candesartan 16 mg Tablet (DIN 02366320) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 15, 2020**. The following grouping was removed from the Critical Supply Product List **September 16, 2020**.

CANDESARTAN CILEXETIL

16 MG TABLET

00002365367	APO-CANDESARTAN	APX	\$ 0.2281
00002445808	AURO-CANDESARTAN	AUR	\$ 0.2281
00002388715	CANDESARTAN	SIV	\$ 0.2281
00002388936	CANDESARTAN	SNS	\$ 0.2281
00002379287	CANDESARTAN CILEXETIL	AHI	\$ 0.2281
00002386526	JAMP-CANDESARTAN	JPC	\$ 0.2281
00002476924	MINT-CANDESARTAN	MPI	\$ 0.2281
00002391201	PMS-CANDESARTAN	PMS	\$ 0.2281
00002380706	RAN-CANDESARTAN	RAN	\$ 0.2281
00002326973	SANDOZ-CANDESARTAN	SDZ	\$ 0.2281
00002366320	TEVA-CANDESARTAN	TEV	\$ 0.2281
00002239092	ATACAND	AZC	\$ 1.2847

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php

